534 related articles for article (PubMed ID: 28373262)
1. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Barr PM; Brown JR; Hillmen P; O'Brien S; Barrientos JC; Reddy NM; Coutre S; Mulligan SP; Jaeger U; Furman RR; Cymbalista F; Montillo M; Dearden C; Robak T; Moreno C; Pagel JM; Burger JA; Suzuki S; Sukbuntherng J; Cole G; James DF; Byrd JC
Blood; 2017 May; 129(19):2612-2615. PubMed ID: 28373262
[TBL] [Abstract][Full Text] [Related]
2. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC; Brown JR; O'Brien S; Barrientos JC; Kay NE; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Devereux S; Barr PM; Furman RR; Kipps TJ; Cymbalista F; Pocock C; Thornton P; Caligaris-Cappio F; Robak T; Delgado J; Schuster SJ; Montillo M; Schuh A; de Vos S; Gill D; Bloor A; Dearden C; Moreno C; Jones JJ; Chu AD; Fardis M; McGreivy J; Clow F; James DF; Hillmen P;
N Engl J Med; 2014 Jul; 371(3):213-23. PubMed ID: 24881631
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib treatment of CLL: the cancer fights back.
Young RM; Staudt LM
Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
Chen LS; Bose P; Cruz ND; Jiang Y; Wu Q; Thompson PA; Feng S; Kroll MH; Qiao W; Huang X; Jain N; Wierda WG; Keating MJ; Gandhi V
Blood; 2018 Nov; 132(21):2249-2259. PubMed ID: 30254130
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
[TBL] [Abstract][Full Text] [Related]
7. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
8. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
Jain N; O'Brien S
Hematol Oncol Clin North Am; 2013 Aug; 27(4):851-60, x. PubMed ID: 23915749
[TBL] [Abstract][Full Text] [Related]
10. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Jaglowski SM; Jones JA; Nagar V; Flynn JM; Andritsos LA; Maddocks KJ; Woyach JA; Blum KA; Grever MR; Smucker K; Ruppert AS; Heerema NA; Lozanski G; Stefanos M; Munneke B; West JS; Neuenburg JK; James DF; Hall N; Johnson AJ; Byrd JC
Blood; 2015 Aug; 126(7):842-50. PubMed ID: 26116658
[TBL] [Abstract][Full Text] [Related]
11. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
12. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
13. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
15. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
16. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
17. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
[No Abstract] [Full Text] [Related]
18. Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
Barrientos J; Rai K
Leuk Lymphoma; 2013 Aug; 54(8):1817-20. PubMed ID: 23617325
[TBL] [Abstract][Full Text] [Related]
19. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
